Who are Phase C: Spironolactone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inspra, Aldactone, Spironolactone (drug), Eplerenone (Night-time), Phase C: Eplerenone, Spironolacton (hexalacton(R)).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phase-c-spironolactone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Phase C: Spironolactone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase C: Spironolactone (Phase C: Spironolactone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-sparing diuretic; Aldosterone antagonist. Area: Cardiovascular.

marketed Potassium-sparing diuretic; Aldosterone antagonist Mineralocorticoid receptor (MR) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Phase C: Spironolactone (Phase C: Spironolactone) — National Institute of Cardiology, Warsaw, Poland. Spironolactone blocks aldosterone receptors in the kidney to reduce sodium reabsorption and potassium excretion, lowering blood pressure and reducing fluid retention.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Phase C: Spironolactone TARGET	Phase C: Spironolactone	National Institute of Cardiology, Warsaw, Poland	marketed	Potassium-sparing diuretic; Aldosterone antagonist	Mineralocorticoid receptor (MR)
Inspra	EPLERENONE	Upjohn	marketed	Aldosterone Antagonist [EPC]	Mineralocorticoid receptor	2002-01-01
Aldactone	spironolactone	Generic (originally Searle/Pfizer)	marketed	Aldosterone Antagonist [EPC]	Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2	1960-01-01
Spironolactone (drug)	Spironolactone (drug)	University of Sao Paulo General Hospital	marketed	Potassium-sparing diuretic; Aldosterone antagonist	Mineralocorticoid receptor (MR)
Eplerenone (Night-time)	Eplerenone (Night-time)	Vanderbilt University Medical Center	marketed	Selective aldosterone antagonist (mineralocorticoid receptor antagonist)	Mineralocorticoid receptor (MR)
Phase C: Eplerenone	Phase C: Eplerenone	National Institute of Cardiology, Warsaw, Poland	marketed	Selective aldosterone antagonist	Mineralocorticoid receptor (MR)
Spironolacton (hexalacton(R))	Spironolacton (hexalacton(R))	Steno Diabetes Center Copenhagen	marketed	Potassium-sparing diuretic; aldosterone antagonist	Mineralocorticoid receptor (MR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-10-28 — Aldactone · 9757394 · Formulation · US
2036-10-28 — Aldactone · 11395828 · Method of Use · US
2036-10-28 — Aldactone · 10888570 · Formulation · US
2036-10-28 — Aldactone · 11389461 · Formulation · US
2036-10-28 — Aldactone · 10660907 · Formulation · US
2036-10-28 — Aldactone · 10624906 · Formulation · US
2036-10-28 — Aldactone · 10493083 · Formulation · US
2036-10-28 — Aldactone · 11491166 · Formulation · US

Sponsor landscape (Potassium-sparing diuretic; Aldosterone antagonist class)

National Institute of Cardiology, Warsaw, Poland · 1 drug in this class
University of Sao Paulo General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phase C: Spironolactone — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-c-spironolactone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing